Explore the current issue of The New England Journal of Medicine (Vol. 395 No. 1).
The two academic authors of the article by Jayne et al., Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609, 1 request retraction of the article because, according ...
To the Editor: In the phase 3 GRADUATE trials of gantenerumab for early Alzheimer’s disease reported by Bateman et al. (Nov. 16 issue), 1 participants receiving gantenerumab had a greater decrease in ...
Though Medicare is launching the GLP-1 Bridge program, offering enrollees temporary discounted access to GLP-1 medications for weight loss, the long-term model to which it was meant to lead was pos ...
A 47-year-old man with heart failure with a reduced ejection fraction and an ICD for the primary prevention of sudden cardiac death presented with an unheralded syncopal event, which had been captured ...
Explore this issue of The New England Journal of Medicine (Vol. 394 No. 23).
Hereditary angioedema is a rare and potentially life-threatening genetic condition characterized by recurrent and debilitating swelling attacks. Lonvoguran ziclumeran (lonvo-z) — an investigational, ...
We randomly assigned patients with type 2 diabetes and chronic kidney disease (defined by an estimated glomerular filtration rate [eGFR] of 50 to 75 ml per minute per 1.73 m 2 of body-surface area and ...
Talquetamab, a bispecific antibody targeting GPRC5D and CD3, has led to durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma in phase 1–2 trials, with a ...
Divergent approaches to psychedelics regulation have led to an environment in which patients, clinicians, and policymakers face conflicting expectations about access, safety, and clinical responsib ...
In this phase 3, double-blind trial, we randomly assigned patients with idiopathic pulmonary fibrosis in a 1:1:1 ratio to receive nerandomilast at a dose of 18 mg twice daily, nerandomilast at a dose ...
Explore this issue of The New England Journal of Medicine (Vol. 394 No. 22).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results